Aquestive Therapeutics Stock Price. Everything You Need To Know About The Aquestive Therapeutics Stock!

Aquestive Therapeutics, Inc. is a company headquartered in Warren, New Jersey, that focuses on identifying, developing, and commercializing products to address unmet medical needs and solve patients’ therapeutic problems. With 130 full-time employees, the firm is engaged in developing orally administered products that provide alternatives to traditional therapies.

Aquestive Therapeutics is advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), including epilepsy. Its CNS portfolio includes Sympazan and Libervant. Additionally, the company has an earlier stage pipeline focused on the treatment of severe allergic reactions, including anaphylaxis.

The firm’s complex molecule pipeline portfolio includes AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology is used to develop non-invasive medicines that offer customized suitability for patients with dysphagia, or trouble swallowing. PharmFilm ensures consistent therapeutic dosing and can be administered without water, providing a convenient and effective treatment option.

As with any investment opportunity, it’s important to conduct thorough research before making any decisions. While we cannot provide financial advice, we encourage you to stay up-to-date with the latest industry news and trends, and to evaluate Aquestive Therapeutics’ financial health, including its stock performance, shares, and market cap. By keeping an eye on key indicators and doing your due diligence, you can make informed decisions about your investments.